- I recommend that you nibble a few shares of PharmaCyte Biotech if interested in a “trade” or a very high-risk long-term buy-and-hold.
- Historically, the company (or its investors) has proved to be quite expert in self-promotion.
- Your entry price per share should be at or below $4.25.
- The direct offering is for 14 million shares plus up to 7 million shares, through warrants, for minimum proceeds of $70 million.
- Gross proceeds from NASDAQ offering for $15 million plus the $70 million direct offering will be used for Phase 2b clinical trials.
For further details see:
PharmaCyte Biotech: Buy The 'Dump'